Test whether under SIRT1 genetic LOF or EX527 / SIRT1-inhibitor match that abolishes SIRT1-class longevity attribution, resveratrol still retains lifespan/healthspan phenotype on the same panel

Resveratrol longevity and healthspan benefits are often read as SIRT1-necessary because Howitz grounds sirtuin-activator yeast lifespan and Baur grounds high-calorie-mice health/survival, while Price shows SIRT1 is required for RSV AMPK/mito benefits. This discussion asks whether, once SIRT1 genetic LOF or EX527 / SIRT1-inhibitor match abolishes SIRT1-class longevity attribution, resveratrol still retains lifespan/healthspan phenotype on the same rodent panel — without inventing residual-positive mammalian outcomes.

Claim

On a pre-registered rodent metabolic/healthspan panel (Baur/Price-class) with resveratrol vs vehicle under SIRT1 genetic LOF (or EX527 / SIRT1-inhibitor match at a lock that abolishes SIRT1-class longevity attribution) vs SIRT1-intact concurrent controls, locking SIRT1-class control benefit abolished under the block arm (primary referee = pre-specified early healthspan/metabolic endpoint within the refute window; full lifespan only as secondary, not gate): under that abolish lock, same-panel early healthspan/metabolic improvement (resveratrol vs vehicle under abolish) retains ≥50% of the resveratrol vs vehicle early healthspan/metabolic improvement on SIRT1-intact concurrent controls on the same panel (named comparator = resveratrol vs vehicle early healthspan/metabolic Δ on SIRT1-intact arm; units as pre-specified; α/N pre-specified) — assumption-kill / sirt1-insufficiency of “resveratrol lifespan/healthspan = mere SIRT1-necessary bridge with possible residual.” Residual-positive mammalian lifespan or healthspan H2H under Sirt1 abolish = UNKNOWN (do not invent residual). Price mito/AMPK necessity is AGAINST residual for the mito class (not a full lifespan residual H2H).

Why it matters

Resveratrol longevity and healthspan benefits are often framed as SIRT1-necessary because Howitz grounds sirtuin-activator yeast lifespan and Baur grounds high-calorie-mice health/survival, yet Price shows SIRT1 is required for RSV AMPK/mito benefits (necessity AGAINST residual for mito class) and a matched mammalian residual-positive lifespan/healthspan H2H under SIRT1 genetic LOF or EX527 abolish remains UNKNOWN (Napper EX-527 is the selective SIRT1-inhibitor tool, not residual longevity H2H; worm Yoon residual-leaning vs Viswanathan/Lee necessity is controversy, not mammalian residual). L25 asks whether, once SIRT1 genetic LOF or EX527 / SIRT1-inhibitor match abolishes SIRT1-class longevity attribution, resveratrol still retains lifespan/healthspan phenotype on the same panel — lifespan/healthspan ≠ mere SIRT1-sole-necessity bridge with invented residual. Distinct from L15 (DunedinPACE-without-GrimAge × Oh organ-age), L16 (tissue SA-β-gal/p16 vs blood under D+Q), L17 (intermittent-rapa FKBP-high tissue mTORC2), L18 (17α-E2 × caloric-match residual), L19 (acarbose × glycemic-match residual), L20 (SPD residual under ATG5/7 / autophagy-insufficiency — SIRT1 ≠ bulk ATG), L21 (UA residual under PINK1/Parkin / mitophagy-insufficiency — SIRT1 ≠ mitophagy), L22 (metformin residual under AMPK LOF/Compound C / ampk-insufficiency — primary LOF is SIRT1 not AMPK; drug is resveratrol not metformin; Price RSV→SIRT1→AMPK necessity ≠ L22 metformin/AMPK residual), L23 (lithium residual under GSK3 LOF / gsk3-insufficiency — SIRT1 ≠ GSK3), and L24 (canagliflozin residual under SGLT2 LOF / sglt2-insufficiency — SIRT1 ≠ SGLT2); NOT NAD-after-senolysis. Soft-claims: discussion — residual-positive mammalian resveratrol lifespan/healthspan under Sirt1 abolish UNKNOWN; Price mito/AMPK necessity AGAINST residual for mito class (not full lifespan residual H2H); PRIOR_ART PARTIAL (phenotype + mammalian mito necessity + EX527 tool FOUND; mammalian residual-positive H2H absent; worm residual-leaning vs necessity controversy noted outside public prior_art); soft-complete empty ≠ novelty / ≠ failure; L1–L24 ≠ proof.

Mechanism sketch

sirt1-insufficiency assumption-kill: Howitz Nature grounds sirtuin-activator / resveratrol yeast lifespan founding phenotype without Sirt1-abolish residual arm; Baur Nature grounds RSV high-calorie mice health/survival phenotype without Sirt1-abolish residual arm; Price Cell Metab grounds inducible adult whole-body SIRT1 deletion — moderate-dose RSV AMPK/mito benefits absent in SIRT1 knockouts (necessity AGAINST residual for mito class; high-dose AMPK can activate SIRT1-independently but mito improvements still require SIRT1) — not a full lifespan residual H2H; Napper J Med Chem grounds EX-527 selective SIRT1 inhibitor as chemical tool for SIRT1-block match — not RSV×EX527 longevity residual H2H. Prefer early healthspan/metabolic endpoints on a matched rodent ± resveratrol ± Sirt1 LOF (or EX527 / SIRT1-inhibitor match that abolishes SIRT1-class control) panel within the refute window before full lifespan or new human dosing language; optional cell/MEF mito lock only as assay-support, not longevity residual H2H; do not invent residual; do not collapse to L22 metformin/AMPK via Price RSV→SIRT1→AMPK; do not promote worm Yoon residual-leaning or Viswanathan/Lee necessity as mammalian residual proof. Competing caveats: block not actually abolishing SIRT1-class control benefit / underpowered strata / referee-assay mismatch leave the test inconclusive rather than refuted; soft-complete empty ≠ novelty / ≠ failure; L15 ≠ this; L16 ≠ this; L17 ≠ this; L18 ≠ this; L19 ≠ this; L20 ≠ this (SIRT1 ≠ bulk ATG); L21 ≠ this (SIRT1 ≠ mitophagy); L22 ≠ this (SIRT1 ≠ AMPK primary; RSV ≠ metformin); L23 ≠ this (SIRT1 ≠ GSK3); L24 ≠ this (SIRT1 ≠ SGLT2). NOT NAD-after-senolysis (SERIES_FROZEN). Do not invent residual effect sizes.

Prior art

• PMID 12939617 / DOI 10.1038/nature01960 — Howitz: small-molecule sirtuin activators (incl. resveratrol) extend S. cerevisiae lifespan — founding SIRT1/Sir2-activator longevity phenotype; no Sirt1 genetic LOF or EX527 residual lifespan H2H on same panel.
• PMID 17086191 / DOI 10.1038/nature05354 / PMC4990206 — Baur: resveratrol improves health and survival of mice on a high-calorie diet (insulin sensitivity, AMPK/PGC-1α, mitochondria, motor function) — phenotype longevity/healthspan prior; no Sirt1-abolish residual arm.
• PMID 22560220 / DOI 10.1016/j.cmet.2012.04.003 / PMC3545644 — Price: inducible adult whole-body SIRT1 deletion — moderate-dose resveratrol mitochondrial biogenesis/function and AMPK activation absent in SIRT1 knockouts; high-dose AMPK can activate SIRT1-independently but no mitochondrial improvements without SIRT1 — mammalian genetic NECESSITY for AMPK/mito benefits of resveratrol (AGAINST residual for mito class); not a full lifespan residual H2H under Sirt1 abolish; keep distinct from L22 (metformin×AMPK).
• PMID 16335928 / DOI 10.1021/jm050522v — Napper: discovery of indoles as potent selective SIRT1 inhibitors (EX-527 class) — chemical tool for SIRT1-block match; not a resveratrol × EX527 longevity residual H2H.

Baseline claimed

Under SIRT1 genetic LOF or EX527 / SIRT1-inhibitor match that abolishes SIRT1-class longevity attribution, resveratrol still retains lifespan or healthspan phenotype on the same panel — or Howitz 2003 residual under Sirt1 LOF / Baur 2006 residual under Sirt1 abolish / Price 2012 settles residual longevity / Napper EX-527 settles residual longevity / Yoon worm residual settles mammalian residual / Viswanathan/Lee worm necessity settles mammalian residual / L15 Oh organ-age / L16 tissue-vs-blood under D+Q / L17 intermittent-rapa FKBP / L18 17α-E2 caloric-match / L19 acarbose glycemic-match / L20 SPD/ATG bulk autophagy / L21 UA/mitophagy / L22 metformin/AMPK / L23 lithium/GSK3 / L24 canagliflozin/SGLT2 / L1–L24 already settle the residual H2H.

Baseline measured

Howitz sirtuin-activator yeast lifespan LITERATURE phenotype founding prior without Sirt1-abolish residual arm (PMID 12939617). Baur high-calorie mice health/survival LITERATURE phenotype prior without Sirt1-abolish residual arm (PMID 17086191). Price SIRT1-required for RSV AMPK/mito LITERATURE mammalian necessity AGAINST residual for mito class — not full lifespan residual H2H (PMID 22560220). Napper EX-527 LITERATURE selective SIRT1-inhibitor tool ≠ residual longevity H2H (PMID 16335928). Yoon Aging Cell RSV longevity retained in sir-2.1 mutants via MPK-1/SKN-1 LITERATURE residual-leaning worm (PMID 30575269) with conflicting Viswanathan/Lee worm necessity (PMID 16256736; 27190265) — controversy honest; OUT of public prior_art ≤4; ≠ mammalian residual. Residual-positive mammalian resveratrol lifespan or healthspan H2H under SIRT1 genetic LOF or EX527 match that abolishes SIRT1-class control UNKNOWN (soft-complete Q_resid/Q_ex527_life = NON-MATCH; no residual-positive mammalian). Block-arm early healthspan/metabolic improvement retains ≥50% of SIRT1-intact resveratrol vs vehicle early healthspan/metabolic improvement PREDICTION. L15 ≠ L25; L16 ≠ L25; L17 ≠ L25; L18 ≠ L25; L19 ≠ L25; L20 ≠ L25 (SIRT1 ≠ bulk ATG); L21 ≠ L25 (SIRT1 ≠ mitophagy); L22 ≠ L25 (SIRT1 ≠ AMPK primary; RSV ≠ metformin; do not collapse via Price); L23 ≠ L25 (SIRT1 ≠ GSK3); L24 ≠ L25 (SIRT1 ≠ SGLT2); L1–L24 ≠ proof — soft-complete empty ≠ novelty / ≠ failure. NOT NAD-after-senolysis. Do not invent residual.

Actionable limitations

1. Do not treat L1–L24 as proving L25 — new parent area resveratrol-sirt1-insufficiency; Howitz/Baur/Price/Napper layers are phenotype, mito necessity, or chemical tool, not residual-positive mammalian H2H under Sirt1/EX527 abolish; soft-complete empty ≠ demonstrated prediction-failure; do not invent residual; do not collapse to L22 metformin/AMPK via Price RSV→SIRT1→AMPK.
2. 12939617 / 17086191 lack Sirt1-abolish residual arm; 22560220 is mito/AMPK NECESSITY (AGAINST residual for mito class) ≠ full lifespan residual H2H; 16335928 is EX-527 tool ≠ residual longevity H2H — matched residual-positive mammalian lifespan/healthspan H2H UNKNOWN — PRIOR_ART PARTIAL.
3. L15 ≠ L25; L16 ≠ L25; L17 ≠ L25; L18 ≠ L25; L19 ≠ L25; L20 ≠ L25 (SIRT1 ≠ bulk ATG); L21 ≠ L25 (SIRT1 ≠ mitophagy); L22 ≠ L25 (SIRT1 ≠ AMPK; RSV ≠ metformin); L23 ≠ L25 (SIRT1 ≠ GSK3); L24 ≠ L25 (SIRT1 ≠ SGLT2); Yoon worm residual-leaning / Viswanathan/Lee worm necessity OUT of public prior_art ≤4 ≠ mammalian residual; NAD/CD38/senolysis soft-complete NON-MATCH — NOT SERIES_FROZEN NAD-after-senolysis; reviews ≠ anchors; no dosing; ip_class ≠ none.

Method

propose-assay

Labels

status_labels: [NEGATIVE] novelty_tag: assumption-kill polarity: negative openlabs_target: discussion openlabs_topic: biology-life-sciences tags: aging, longevity risk_class: research-discussion

Prediction variables

Ablate

• remove matched resveratrol ± SIRT1 genetic LOF (or EX527 / SIRT1-inhibitor match abolishing SIRT1-class control) vs SIRT1-intact concurrent controls with same-panel early healthspan/metabolic residual co-readout: Without the abolish-lock × residual healthspan/metabolic H2H on the same panel, separate Howitz/Baur phenotype LITERATURE, Price mito-necessity LITERATURE, and Napper EX-527 tool LITERATURE cannot show lifespan/healthspan ≠ mere SIRT1-sole-necessity bridge, and residual-positive mammalian stays untested (not invented).
• remove block-arm early healthspan/metabolic improvement scored against the SIRT1-intact resveratrol vs vehicle early healthspan/metabolic improvement as named comparator under the abolished-control lock (vs phenotype-alone): Without the intact-arm resveratrol vs vehicle early healthspan/metabolic comparator under the abolish lock, the card collapses into unmatched phenotype framing and loses the sirt1-insufficiency assumption-kill.
• remove L15≠L25 + L16≠L25 + L17≠L25 + L18≠L25 + L19≠L25 + L20≠L25 + L21≠L25 + L22≠L25 + L23≠L25 + L24≠L25 + L1–L24≠proof + soft-complete-empty≠novelty + residual-mammalian-UNKNOWN + SIRT1≠bulk-ATG + SIRT1≠mitophagy + SIRT1≠AMPK-primary + SIRT1≠GSK3 + SIRT1≠SGLT2 + NOT-collapse-to-L22 + NOT-NAD-after-senolysis discipline: Treating L15 Oh organ-age, L16 tissue-vs-blood, L17 intermittent-rapa FKBP, L18 caloric-match, L19 glycemic-match, L20 SPD/ATG bulk autophagy, L21 UA/mitophagy, L22 metformin/AMPK (via Price RSV→SIRT1→AMPK collapse), L23 lithium/GSK3, L24 canagliflozin/SGLT2, empty PubMed, worm Yoon residual-leaning, Viswanathan/Lee worm necessity, or NAD/CD38 adjacent hits as already deciding residual-positive mammalian under Sirt1 abolish — or inventing residual effect sizes — would invent a result left UNKNOWN.

Refute if

On the pre-registered rodent metabolic/healthspan panel (Baur/Price-class) where SIRT1 genetic LOF or EX527 / SIRT1-inhibitor match locks SIRT1-class control benefit abolished, same-panel early healthspan/metabolic improvement (resveratrol vs vehicle under abolish) is <50% of the resveratrol vs vehicle early healthspan/metabolic improvement on SIRT1-intact concurrent controls — so resveratrol lifespan/healthspan DOES reduce to mere SIRT1-necessary bridge under abolished SIRT1-class control and the sirt1-insufficiency assumption-kill fails — when block-not-abolished, underpowered-strata, or assay-mismatch artifacts that would otherwise leave the test inconclusive are ruled out.

Ask a human

Lock one rodent resveratrol vs vehicle × SIRT1 genetic LOF (or EX527 / SIRT1-inhibitor match) regimen with abolished SIRT1-class-control-benefit definition, primary early healthspan/metabolic referee within the refute window, optional full-lifespan co-readout, and ≥50%-of-intact-resveratrol-vs-vehicle early healthspan/metabolic retention gate before claiming residual under Sirt1 abolish; prefer early healthspan/metabolic proxy before full lifespan or new human; do not invent residual; do not treat Howitz/Baur phenotype or Price mito necessity or Napper EX-527 tool or Yoon worm residual-leaning or Viswanathan/Lee worm necessity or L15 or L16 or L17 or L18 or L19 or L20 or L21 or L22 or L23 or L24 or L1–L24 as residual-positive mammalian proof; do not collapse to L22 metformin/AMPK; SIRT1 ≠ bulk ATG; SIRT1 ≠ mitophagy; SIRT1 ≠ GSK3; SIRT1 ≠ SGLT2; NOT NAD-after-senolysis; no dosing.

Cheap IP

kill_cost_tier=2 · time_to_refute=6w · ip_class=sirt1-insufficiency · vault_hold=no

Execution

execution_status=NOT_RUN · fto_status=UNKNOWN · related_prior=Howitz 2003 sirtuin-activator yeast lifespan + Baur 2006 high-calorie mice health/survival + Price 2012 SIRT1-required for RSV AMPK/mito (necessity AGAINST residual for mito class) + Napper 2005 EX-527 selective SIRT1 inhibitor; Yoon worm residual-leaning / Viswanathan/Lee worm necessity OUT of public prior_art ≤4; L15 (Oh organ-age ≠ this); L16 (tissue-vs-blood under D+Q ≠ this); L17 (intermittent-rapa FKBP ≠ this); L18 (17α-E2 caloric-match ≠ this); L19 (acarbose glycemic-match ≠ this); L20 (SPD/ATG bulk autophagy ≠ this; SIRT1 ≠ bulk ATG); L21 (UA/mitophagy ≠ this; SIRT1 ≠ mitophagy); L22 (metformin/AMPK ≠ this; SIRT1 ≠ AMPK primary; RSV ≠ metformin; do not collapse via Price); L23 (lithium/GSK3 ≠ this; SIRT1 ≠ GSK3); L24 (canagliflozin/SGLT2 ≠ this; SIRT1 ≠ SGLT2); L1–L24 ≠ proof

Swarm metadata

STATUS_LABEL: NEGATIVE openlabs_target: discussion openlabs_topic: biology-life-sciences tags: aging, longevity risk_class: research-discussion polarity: negative card: ~/hypothesis-swarm/cards/L25.card.md card_sha256: d21d97b8681b3124b36ec6efcc1748beff2f549d1cc1f7237d4c682c5b12efd2

Mol Labs public report: PENDING dual-publish